This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
GERMANTOWN, Maryland, and HILDEN,
June 6, 2013 /PRNewswire/ --
QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced that a U.S. reference laboratory customer of its HPV-related products used for cervical cancer screening has made public on
June 6 a new non-exclusive agreement to consolidate the purchase of products used for women's health diagnostics with a competitor supplier.
QIAGEN has been informed that its HPV-related products will continue to be offered by this customer, and also looks forward to working with this customer to continue the strong growth pace of its sales of other products from its portfolio.
QIAGEN offers the industry-leading test for cervical cancer detection, while the competitor product to be added by this customer to its offering fails to address key physician and patient demands for HPV testing. The
digene HC2 Test is the "gold standard" FDA-approved molecular test for HPV screening based on annual sales and testing volumes, with more than 90 million tests delivered worldwide since its market introduction. It is supported by clinical data from more than 300 clinical studies in independent, peer-reviewed publications involving more than one million women as well as being the only test proven to support implementation of new five-year interval U.S. screening guidelines.
QIAGEN sees no need at this time to revise its guidance for 2013, and expects that sales related to this development represent less than 2% of its anticipated total net sales for 2014. QIAGEN further expects that sales related to products used in HPV screening in the U.S. to represent less than 10% of total net sales in 2014.
QIAGEN N.V., a
Netherlands holding company, is the leading global provider of Sample & Assay Technologies that are used to transform biological materials into valuable molecular information. Sample technologies are used to isolate and process DNA,
RNA and proteins from biological samples such as blood or tissue. Assay technologies are then used to make these isolated biomolecules visible and ready for interpretation. QIAGEN markets more than 500 products around the world, selling both consumable kits and automation systems to customers through four customer classes:
Molecular Diagnostics (human healthcare),
Applied Testing (forensics, veterinary testing and food safety),
Pharma (pharmaceutical and biotechnology companies) and
Academia (life sciences research). As of
March 31, 2013, QIAGEN employed approximately 4,000 people in more than 35 locations worldwide. Further information can be found at
Certain of the statements contained in this news release may be considered forward-looking statements within the meaning of Section 27A of theU.S.Securities Act of 1933, as amended, and Section 21E of theU.S.Securities Exchange Act of 1934, as amended. To the extent that any of the statements contained herein relating to QIAGEN's products, markets, strategy or operating results, including without limitation its expected operating results, are forward-looking, such statements are based on current expectations and assumptions that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations, regulatory processes and dependence on logistics), variability of operating results and allocations between customer classes, the commercial development of markets for our products in applied testing, personalized healthcare, clinical research, proteomics, women's health / HPV testing and nucleic acid-based molecular diagnostics; changing relationships with customers, suppliers and strategic partners; competition; rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN's products (including fluctuations due to general economic conditions, the level and timing of customers' funding, budgets and other factors); our ability to obtain regulatory approval of our products; difficulties in successfully adapting QIAGEN's products to integrated solutions and producing such products; the ability of QIAGEN to identify and develop new products and to differentiate and protect our products from competitors' products; market acceptance of QIAGEN's new products, the consummation of acquisitions, and the integration of acquired technologies and businesses. For further information, please refer to the discussions in reports that QIAGEN has filed with, or furnished to, theU.S.Securities and Exchange Commission (SEC).Contacts:Public Relations: Dr.
Thomas Theuringer Director Public Relations +49-2103-29-11826 +1-240-686-7425 Email:
firstname.lastname@example.org://www.twitter.com/qiagenhttp://www.qiagen.com/About-Us/Press-and-Media/Investor Relations:John Gilardi VP Corporate Communications +49-2103-29-11711 +1-240-686-2222
Peter Vozzo Director, Global Investor Relations +1-240-686-7400 Email:
SOURCE Qiagen N.V.